MENU. Combining international resources with a boutique focus
|
|
- Derick McDaniel
- 5 years ago
- Views:
Transcription
1 Life Sciences Key Contacts Andrea L.C. Reid Partner Boston David S. Rosenthal Partner New York Mélanie Thill-Tayara Partner Paris Translate Page MENU Hatch-Waxman Litigation Digital Health Combining international resources with a boutique focus Innovative leaders in today's competitive life sciences industry rely on Dechert as their strategic adviser to capitalize on business opportunities, handle disputes and resolve challenges through smart, real-world solutions. Dechert is recognized around the globe for successfully navigating the most complex issues confronting life sciences companies from start-ups to multinationals in pharmaceuticals, biotechnology, drug discovery, genomics, diagnostics, medical devices, biosimilars, and digital health as well as the industry s most active investment banks, venture/growth capital firms and research institutions. Our team brings the entrepreneurial energy and technical expertise required to work alongside our clients in their most sophisticated matters.
2 Cross-border work is our hallmark. With Dechert's global footprint, we collaborate seamlessly to help our clients establish or expand their international presence. Our life sciences team works every day in leading biotech hotbeds in the U.S., UK, Europe, Middle East, Russia and Eastern Europe, and East Asia. Excellence Across the Product Lifecycle Dechert s integrated mix of practice and sector experience provides our life sciences clients with insightful and efficient support throughout the product lifecycle from discovery through development, clinical testing, promotion and sales. We draw on our intellectual property, corporate, securities, litigation, antitrust, international arbitration, international trade, tax, employment and labor lawyers to provide comprehensive transactional, regulatory and dispute resolution services. We are proud to be recognized as a leader in life science legal services. Chambers Global has ranked us among the top legal advisors worldwide for Pharma/Life Sciences ( inclusive). We are ranked first for life sciences in France by Chambers Europe ( ) and The Legal 500 placed our firm among the top legal advisors in the Life Sciences/Healthcare sector in France, the U.S. and UK ( ). Innovative leaders in today's competitive life sciences industry rely on Dechert as their strategic adviser to capitalize on business opportunities, handle disputes and resolve challenges through smart, real-world solutions.dechert is recognized around the globe for successfully navigating the most complex issues confronting life sciences companies from start-ups to multinationals in pharmaceuticals, biotechnology, drug discovery, genomics, diagnostics, medical devices, biosimilars, and digital health as well as the industry s most active investment banks, venture/ growth capital firms and research institutions. Our team brings the entrepreneurial energy and technical expertise required to work alongside our clients in their most sophisticated matters.cross-border work is our hallmark. With Dechert's global footprint, we collaborate seamlessly to help our clients establish or EXPERIENCE Ipsen, a global specialty-driven pharmaceutical group, in its $US1.0 billion acquisition of the global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-u.s. and PharmaEngine for Taiwan. The transaction also includes Merrimack s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection. Celgene Corporation, a global biopharmaceutical company, in the acquisition of a 10% stake in Juno Therapeutics, Inc. as part of a 10-year collaboration for the development and commercialization of immunotherapies worth approximately US$1 billion. Winner of LMG Life Sciences Collaboration Deal of the Year award in 2015, this acquisition represents the
3 largest up-front sum for a biotechnology licensing agreement ever, according to Bloomberg Intelligence. As many analysts have noted, this collaboration has the potential to eradicate many forms of cancer over the next 10 years. Dechert has also represented Celgene in several other domestic and cross-border licensing and M&A transactions, including its collaboration with Jounce Therapeutics for US$2.6 billion (including milestone payments), recognized as "Deal of the Year" in 2017 by the New England Venture Capital Association, as well as its collaboration with Agios Pharmaceuticals for US$1.2 billion (including option exercise and future milestones), and the acquisition of Quanticel Pharmaceuticals as part of its up to US$400 million buy-to-build acquisition. CVS Health, a pharmacy innovation company, in a series of antitrust-sensitive billion dollar deals, including its US$12.7 billion acquisition of Omnicare. A public opposition campaign called for the Federal Trade Commission (FTC) to conduct a full second request investigation, alleging that CVS would dominate pharmacy across channels. After working with the FTC, Dechert showed that the deal would improve patient care and lower costs and that a full second request investigation was not warranted. Dechert also guided CVS Health in its US $1.9 billion acquisition of Target s pharmacy and clinic businesses and served as antitrust counsel to CVS Health in its joint venture with Cardinal Health, forming the largest generic drug sourcing entity in the U.S. The work of Dechert s antitrust/competition team on the CVS Health/Target transaction received a LMG Life Sciences M&A impact deal of the Year award (2016). The underwriters, led by Citigroup Global Markets Inc. and Jefferies LLC, in the initial public offering and cross-border listing of French radiopharmaceutical company Advanced Accelerator Applications S.A. (AAA) on NASDAQ. AAA was seeking to advance the molecular nuclear therapy branch of its business, to heighten its corporate profile and to diversify its investor base by gaining access to the U.S. capital markets. AAA accomplished these goals by capitalizing on the positive results from the pivotal Phase 3 trial for its novel lead therapeutic candidate, Lutathera, for the treatment of patients with positive midgut neuroendocrine tumors to conduct a successful US$86.5 million initial public offering of American Depositary Shares and listing on the NASDAQ Global Select Market. AAA s IPO priced within its anticipated range despite uneven market conditions. AAA s U.S. IPO not only enabled AAA to access U.S. investors, but AAA used a portion of the proceeds of the offering to establish a permanent Lutathera manufacturing facility in Millburn, New Jersey; further establishing a favorable profile for future capital raising transactions in the U.S. Johnson & Johnson (J&J) and its affiliate Ethicon, a medical equipment developer within the J&J family of companies, in its strategic collaboration with Google, working with the Life Sciences team on advancing surgical robotics to benefit surgeons, patients and health care systems. The companies will bring together capabilities, intellectual property and expertise to create an innovative robotic-assisted surgical platform capable of integrating advanced technologies with the goal of improving health care delivery in the operating room. The companies seek to develop new robotic tools and capabilities for surgeons and operating room professionals that integrate best-in-class medical device technology with leading-edge robotic systems, imaging and data analytics. Dechert s work on this collaboration received a LMG Life Sciences Collaboration Deal of the Year award (2015). Bristol-Myers Squibb (BMS), a global biopharmaceutical company, in an important victory by securing the reversal by the Pennsylvania Supreme Court of a lower court s US$28 million
4 judgment against BMS for violating Pennsylvania s Unfair Trade Practices and Consumer Protection Law. The decision was significant as at least 26 other states had filed similar lawsuits citing unfair and deceptive practices by pharmaceutical companies. Endo Pharmaceuticals, a global specialty pharmaceutical company, in the Federal Trade Commission s (FTC) first litigation challenge to a patent settlement agreement including a no authorized generic provision. The Dechert team developed a litigation strategy that included a legal challenge to the agency s statutory authority to file federal court litigation and to seek disgorgement. The result was a settlement of all of Endo s litigation with the FTC on favorable terms, requiring no admission of wrongdoing, no monetary payment and prohibitions consistent with Endo s current approach to patent settlements. Also represented Endo in a series of related Hatch-Waxman patent infringement actions filed against seven generic companies regarding its OPANA ER tablets, which at its peak, was Endo s second highest-selling product with US$300 million in annual sales. The Dechert team prevailed in a five-week trial in New York against seven generic companies, and later, secured Federal Circuit affirmance of its hard-fought patent trial victory, so that none of the generic versions of OPANA ER involved can come to market before Endo s patents expire in Dechert also prevailed in two separate patent trials in the District of Delaware with respect to an additional patent that Endo exclusively licensed from Mallinckrodt. The cases are currently on appeal, and the defendants are enjoined from selling their generic products through Pfizer, a global biopharmaceutical company, in multiple pharmaceutical mass torts pending in various courts around the U.S. The Reglan litigation is one of the largest coordinated pharmaceutical mass torts in the country, with more than 2,000 cases pending in Philadelphia County alone. Reglan, and its generic counterpart, metoclopramide, is commonly used to treat intractable gastroesophageal reflux disease and diabetic gastroparesis. Dechert plays a key strategic role for Pfizer, advising on legal issues including preemption and innovator liability the potential liability of brand pharmaceutical manufacturers for injuries allegedly sustained by plaintiffs who took only the generic version of the drug made by another manufacturer and coordinating efforts to resolve all Reglan/metoclopramide claims pending against Wyeth in Philadelphia and elsewhere. Dechert also represents Pfizer in separate multidistrict litigations in state and federal courts concerning birth defects in infants allegedly caused by the mothers use of the antidepressant Zoloft. In 2009, when we took over Pfizer s defense in a mass-tort litigation concerning hormone therapy, more than 1,500 cases were pending in Pennsylvania alone; the last case in Philadelphia was settled in Nimbus Apollo, Inc., a biotherapeutics company that develops drugs to treat non-alcoholic steatohepatitis, in developing and implementing a drug discovery patent strategy and, later, a focused patent strategy protecting the lead drug candidate in human clinical trials. Subsequently, the company was acquired by Gilead Sciences for US$1.2 billion. In 2016, Dechert was honored by the Financial Times in the "Legal Expertise" category entitled " Enabling Clients to Innovate" for the innovative IP strategy work done on behalf of the drug discoverer to underpin the deal with Gilead. LIFECYCLE MANAGEMENT
5 Dechert s life sciences team represents clients throughout all stages of their products lifecycle, from discovery through development, clinical testing, promotion and sales. As new complexities arise, we draw efficiently on the talents of the firm s intellectual property, corporate, securities, antitrust, international trade, tax, employment and labor and litigation attorneys. FINANCINGS Clients turn to us to capture and structure capital to support the long development and commercialization process, ranging from early-stage venture financings and strategic equity investments to complex public offerings of equity and debt. MERGERS AND ACQUISITIONS Dechert structures successful deals, ensuring speed-to-market execution and protecting our clients interests in all phases of a transaction. Our teams routinely handle domestic and cross-border mergers, acquisitions, divestitures, spin-offs, joint ventures strategic alliances and collaborative arrangements. Mergermarket ranked us among top M&A legal advisors for total volume of M&A deals in the healthcare and life sciences industry in North America (2015 ). LICENSING AND COLLABORATION AGREEMENTS Our lawyers negotiate and structure agreements across the global supply chain to optimize financing, development, manufacturing and distribution for our clients. We recently were ranked among the top law firms for volume and value of Biotech and Pharma licensing agreements for Global, North America and Europe by BioPharmInsight (2015). We also handle the full range of research, development and consulting agreements, venture formation and joint venture agreements, manufacturing and supply agreements, marketing and distribution agreements, and technology transfer arrangements. INTELLECTUAL PROPERTY
6 Dechert provides clients with comprehensive, long-range strategic advice to help them protect and enhance their IP positions, both to create a competitive advantage and maximize value. Our life sciences IP counseling team works in concert with our transactional IP team on IP-driven commercial transactions, including strategic alliances, co-promotion agreements, discovery and development licenses, co-development arrangements, acquisitions and related due diligence, joint ventures, and exclusive provider and distribution deals. HATCH-WAXMAN Drawing on a high degree of technical and scientific sophistication, our legal team asserts clients intellectual property rights in the face of Hatch-Waxman Act and Abbreviated New Drug Application (ANDA) applications. Branded pharmaceutical leaders rely on our trial lawyers, appellate lawyers and Ph.D.-level subject matter experts to draw on our broad experience in this area to create and execute successful defense strategies. ANTITRUST/COMPETITION Our antitrust lawyers in the U.S. and Europe combine deep antitrust expertise with industry knowledge to help life sciences clients defend litigation, including class actions, and navigate Federal Trade Commission (FTC) and European Commission (EC) investigations into mergers, as well as various aspects of intellectual property and other strategies. Leading life sciences companies have relied on our team to handle litigation challenges and agency investigations involving, among other things, pay for delay settlements, patent listings, alleged sham patent litigation, and claimed abuse of Risk Evaluation and Mitigation Strategy ( REMS) processes. PRODUCT LIABILITY We fiercely defend our clients in product liability and consumer fraud claims of all kinds, drawing on the skills of one of the top product liability practices in the U.S. We are often called upon to handle new strains of product liability suits, such as so-called innovator liability, in which plaintiffs sue name-brand drug makers based on alleged injuries they sustained by taking a generic version of the branded drug that s manufactured by a different company.
7 COMMERCIAL LITIGATION AND INTERNATIONAL ARBITRATION Clients count on our team s creativity and experience in the courts and various international arbitration regimes to handle disputes arising out of licensing, collaboration, asset purchase, distribution and other agreements. INVESTIGATIONS AND DEFENSE We guide our clients through complex internal investigations, defend them in parallel civil actions and negotiate the most advantageous outcomes for their businesses. Our clients in this arena include corporations, audit committees and senior executives. EMPLOYMENT, BENEFITS AND TAX ISSUES Life sciences clients rely on our cross-functional team for assistance with the full range of employment, benefits and tax issues, both domestic and cross border, relating to corporate transactions, complex disputes and litigation. Related Professionals SAMUEL B. ABRAMS Partner New York T JOHN E. ALESSI Associate Boston T ARIF H. ALI Partner Washington, D.C. T London T KURTIS M. ANDERSON PH.D. Patent Agent New York T
8 JOSEPH W. ARICO PH.D. Patent Agent Boston T KATHERINE ARMSTRONG Counsel New York T View All Related Professionals Related Practice Areas Finance Mergers and Acquisitions Antitrust/Competition Intellectual Property Product Liability and Mass Torts Complex Commercial Litigation
MENU. Providing health care industry leaders with worldwide solutions to optimize their performance and profitability
Health Care Key Contacts Susan M. Hendrickson Partner Princeton +1 609 955 3206 Mike Cowie Partner Washington, D.C. +1 202 261 3339 Translate Page MENU Digital Health Providing health care industry leaders
More informationDechert and Life Sciences A GLOBAL MULTI-DISCIPLINARY TEAM. EXPERT LAWYERS. ADVICE THAT ADDS VALUE.
Dechert and Life Sciences A GLOBAL MULTI-DISCIPLINARY TEAM. EXPERT LAWYERS. ADVICE THAT ADDS VALUE. D 1 In France, Dechert life sciences lawyers handle their clients most complex and strategic matters
More informationAntitrust/Competition
Antitrust/Competition Key Contacts Steven E. Bizar Partner Philadelphia +1 215 994 2205 Michael L. Weiner Partner New York +1 212 698 3608 Translate Page MENU Cartel Investigations Merger Clearance Merger
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationLitigation & Dispute Resolution
Disputes arise from sources ranging from internal matters, such as employee or whistleblower claims, to external matters, such as contract disputes, government investigations or protecting intellectual
More informationAt a glance dechert.com
At a glance Attorney advertising. Prior results do not guarantee a similar outcome. Dechert is a global specialist law firm. Focused on sectors with the greatest complexities, legal intricacies and highest
More informationInternational. Contact us to learn more about our International Tax practice. Partnering With Our Colleagues. U.S. corporate tax directors and
International Tax U.S. corporate tax directors and background, tactical judgment, and Caplin & Drysdale s international tax lawyers individuals holding foreign assets face problem-solving savvy to resolving
More informationM. Gabrielle Hils Of Counsel
M. Gabrielle Hils Of Counsel gabrielle.hils@dinsmore.com Cincinnati, OH Tel: (513) 977-8175 Gabrielle's diverse experience and knowledge of complex litigation, including class action proceedings, has allowed
More informationLitigation
www.glaserweil.com Litigation Over the years, the litigation attorneys at Glaser Weil have earned victory after victory for a broad range of clients, thus cementing our reputation as a premier litigation
More informationGLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
More informationTokyo Office. Local Roots OVER FOUR DECADES IN JAPAN. Japanese attorneys. Gaikokuho Jimu Bengoshi. Tax attorneys.
TOKYO Local Roots OVER FOUR DECADES IN JAPAN Baker & McKenzie (Gaikokuho Joint Enterprise) is one of Japan s leading international law firms as well as one of its oldest. It is also the largest foreign
More informationQ UPDATE EXECUTIVE RISK SOLUTIONS CASES OF INTEREST D&O FILINGS, SETTLEMENTS AND OTHER DEVELOPMENTS
EXECUTIVE RISK SOLUTIONS Q1 2018 UPDATE CASES OF INTEREST U.S. SUPREME COURT FINDS STATE COURTS RETAIN JURISDICTION OVER 1933 ACT CLAIMS STATUTORY DAMAGES FOR VIOLATION OF TCPA FOUND TO BE PENALTIES AND
More informationAutomotive and Transportation
Automotive and Transportation A sector focus fueled by powerhouse legal practices and industry experience Dechert s automotive and transportation sector team mobilizes the firm s internationally recognized
More informationThe Renaissance Centre, Suite North King Street Wilmington, DE Phone: Fax:
2018 Whiteford, Taylor & Preston LLC Daniel A. Griffith Partner The Renaissance Centre, Suite 500 405 North King Street Wilmington, DE 19801-3700 Phone: 302.357.3254 Fax: 302.357.3274 Email: dgriffith@wtplaw.com
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C SCHEDULE TO. Advanced Accelerator Applications S.A. (Name of Subject Company)
QuickLinks -- Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the
More informationGlobal Finance. Asset-backed securities and derivatives
Global Finance Asset-backed securities and derivatives Collateralized loan obligations Commercial mortgage-backed securities Commercial real estate finance Fund finance Leveraged finance Life sciences
More informationDechert and the Law Firm of Hassan Mahassni
Dechert and the Law Firm of Hassan Mahassni PROVIDING COMPREHENSIVE LEGAL SERVICES IN MENA, ASIA AND BEYOND MAHASSNI 900+ LAWYERS 40+ LANGUAGES 29 OFFICES 14 COUNTRIES 1 ASSOCIATION 2 Attorney advertising.
More informationPATRICK S. COFFEY. Chicago, IL office: office:
PATRICK S. COFFEY Partner Milwaukee, WI Chicago, IL office: 312.523.2080 office: 414.978.5538 email: patrick.coffey@ Overview When clients are faced with difficult problems, Pat puts them at ease. He uses
More informationOur Practice Areas. Corporate and Business Law. Employment and Labour Law. Antitrust. Banking Law ADR 1 / 6
Petra Law Firm provides legal services in various challenging legal fields and bring to its clients the utmost advice in the following legal sectors, but not limited to: Corporate and Business Law Employment
More informationHealth Care Practice Center
Health Care Practice Center Power your practice. 800.372.1033 bna.com/bloomberglaw Seamlessly integrated intelligence. Practice pages Navigate the nuances of health care law. Bloomberg Law s Health Care
More informationHEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036
Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com
More informationABLYNX ANNOUNCES FULL YEAR RESULTS FOR 2007
ABLYNX ANNOUNCES FULL YEAR RESULTS FOR 2007 GHENT, Belgium, 28 February 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived
More informationSecurities, Financial and Directors & Officers Litigation. Practice Overview
Securities, Financial and Directors & Officers Litigation Practice Overview Seyfarth Shaw LLP Capabilities Our Securities, Financial and Directors & Officers Litigation Practice Group attorneys help companies
More informationIn every phase of the private equity investment life cycle, we help clients accomplish their investment objectives by:
Private Equity Key Contacts Henry N. Nassau Partner Philadelphia +1 215 994 2138 Mark E. Thierfelder Partner New York +1 212 698 3804 Dechert is among the most active law firms in the private equity industry.
More informationAgreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 003 Summary of Agreements Filed in FY 007 A Report by the Bureau of Competition
More informationlitigation and investigation services when the stakes are high, every decision is critical
litigation and investigation services when the stakes are high, every decision is critical LITIGATION SERVICES ECONOMIC DAMAGES VALUATION SERVICES FORENSIC & INVESTIGATIVE ACCOUNTING INTELLECTUAL PROPERTY
More informationMomenta Pharmaceuticals, Inc.
PROSPECTUS SUPPLEMENT (To the Prospectus dated February 27, 2015) 5MAR200419235391 7,250,000 Shares Momenta Pharmaceuticals, Inc. Common Stock We are offering 7,250,000 shares of our common stock. Our
More informationABOUT THE FIRM HOSPITALITY PRACTICE GROUP CASUALTY LITIGATION PRACTICE GROUP ANDREW J. CONNOLLY PRINCIPAL MATTHEW D.
ABOUT THE FIRM HOSPITALITY PRACTICE GROUP CASUALTY LITIGATION PRACTICE GROUP ANDREW J. CONNOLLY PRINCIPAL MATTHEW D. JOHNSON ASSOCIATE ABOUT THE FIRM ABOUT US Offices: Allentown: Phone: (610) 433-0193
More informationINSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 OncoSec Medical (Nasdaq/ONCS)
More informationAVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. May 8, 2018 AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationFinance for the future of law. How Burford helps businesses
Finance for the future of law How Burford helps businesses Burford Capital is a pioneer in litigation funding. WALL STREET JOURNAL Burford [is] really innovating and expanding the way we think of litigation
More informationGregory A. Harrison Partner
Gregory A. Harrison Partner greg.harrison@dinsmore.com Cincinnati, OH Tel: (513) 977-8314 A member of the firm's Board of Directors, Greg is a proven litigator. First as a trial attorney with the United
More informationIntellipharmaceutics Announces First Quarter 2018 Results
April 16, 2018 Intellipharmaceutics Announces First Quarter 2018 Results TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationUNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA NOTICE OF CLASS CERTIFICATION AND PARTIAL PROPOSED BIOVAIL SETTLEMENT
UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA NOTICE OF CLASS CERTIFICATION AND PARTIAL PROPOSED BIOVAIL SETTLEMENT If You Bought Wellbutrin XL or its Generic Equivalent, You May
More informationLDD «Barcode» Postal Service: Please do not mark barcode Claim#: LDD-«Claim8» - «CkDig» «First1» «Last1» «Addr2» «Addr1» «City», «St» «Zip»
Lidoderm End-Payor Notice Administrator c/o KCC Class Action Services P.O. Box 43491 Providence, RI 02940-3491 LDD «Barcode» Postal Service: Please do not mark barcode Claim#: LDD-«Claim8» - «CkDig» «First1»
More informationIP ISSUES IN MERGERS & ACQUISITIONS
IP ISSUES IN MERGERS & ACQUISITIONS Louis Beardell, James Carrigan, and Rachelle Dubow June 6, 2017 2016 Morgan, Lewis & Bockius LLP Key IP Issues in Mergers & Acquisitions I. IP due diligence: scope,
More informationWhat Do Investors Need to Know About Your Dealings with the FDA? Practice Pointers for Health Sciences Companies
Health Sciences Speaker Series What Do Investors Need to Know About Your Dealings with the FDA? Practice Pointers for Health Sciences Companies Aline Fairweather Scott Jones Sharon Klein Pamela Palmer
More informationCorporate, Finance & Acquisitions We make our clients' business goals - our legal objective
We make our clients' business goals - our legal objective Having successfully negotiated, documented and closed billions of dollars of commercial transactions and investments into the U.S. and abroad,
More informationMeasuring the return from pharmaceutical innovation 2017 Methodology
Measuring the return from pharmaceutical innovation 2017 Methodology Contents Introduction 01 Methodology 02 Original cohort 03 Extension cohort 03 Assets evaluated 03 Methodology amendments and restatements
More informationMcKesson Corporation J.P. Morgan Healthcare Conference
McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in
More informationIP ISSUES IN MERGERS & ACQUISITIONS
M&A ACADEMY IP ISSUES IN MERGERS & ACQUISITIONS Louis Beardell, James Carrigan, and Rachelle Dubow March 29, 2016 Key IP Issues in Mergers & Acquisitions I. IP due diligence: scope, validity, ownership,
More informationDechert Survey of Securities Fraud Class Actions Brought Against Life Sciences Companies. August 2004
d Dechert Survey of Securities Fraud Class Actions Brought Against Life Sciences Companies August 2004 Life Sciences Suits on the Rise Now, more than ever, life sciences companies are in the sights of
More informationBRIAN E. O DONNELL. Practice Areas. Areas of Emphasis. Overview
BRIAN E. O DONNELL Practice Areas Litigation Insurance and Reinsurance Law Products Liability, Toxic Tort and Mass Tort Alternative Dispute Resolution Cyber Liability Areas of Emphasis Commercial Litigation
More informationHealthcare is changing We re changing healthcare. George S. Barrett Chairman and Chief Executive Officer
Healthcare is changing We re changing healthcare. George S. Barrett Chairman and Chief Executive Officer 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8th Copyright 2016, Cardinal Health,
More informationTopotarget and BioAlliance Pharma enter into merger agreement to create a leading orphan oncology company
To NASDAQ OMX Copenhagen A/S Announcement no. 06-14 / Copenhagen, April 16, 2014 Topotarget A/S Symbion Fruebjergvej 3 DK-2100 Copenhagen Denmark T: +45 39 17 83 92 E: enquiries@topotarget.com Comp reg.:
More informationCase Study: Life Cycle of a Successful VC- Funded Global High-Tech Venture
Case Study: Life Cycle of a Successful VC- Funded Global High-Tech Venture 2015 Bierce & Kenerson, P.C. CASE STUDY Life Cycle of a Successful VC-Funded Global High-Tech Venture or How a small, privately
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSTUDIO LEGALE DELFINO E ASSOCIATI WILLKIE FARR & GALLAGHER LLP
Studio Legale Delfino e Associati Willkie Farr & Gallagher LLP In 2000, the New York law firm Willkie Farr & Gallagher LLP joined the Italian law firm Delfino e Associati creating Studio Legale Delfino
More informationMATTHEW T. SCHELP. St. Louis, MO office:
MATTHEW T. SCHELP Partner St. Louis, MO office: 314.480.1772 email: matthew.schelp@ Overview A former federal prosecutor, Matt concentrates his practice in the areas of compliance, internal investigations,
More informationProfessional liability
Professional liability 360 www.mpplaw.com about our Practice Established in 1969, Morris Polich & Purdy llp has a rich, prestigious history of representing all types of professionals. Our many services
More informationPRESS RELEASE. Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
PRESS RELEASE Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA )
More informationAsia Pacific Practice. Insight into Asia Understanding Your Business Securing Your Goals
Asia Pacific Practice Insight into Asia Understanding Your Business Securing Your Goals On the surface, law firms are virtually indistinguishable from each other. Finding the right law firm for your business,
More informationFranklin Biotechnology Discovery Fund Advisor Class
Franklin Discovery Fund Advisor Class Equity Product Profile Product Details 1 Fund Assets $1,391,510,431.86 Fund Inception Date 09/15/1997 Number of Issuers 91 NASDAQ Symbol FTDZX Maximum Sales Charge
More informationKymberly Kochis. P: E:
ATTORNEY BIOGRAPHY Kymberly Kochis Partner New York P: +1.212.389.5068 E: kymberlykochis@eversheds-sutherland.com Education J.D., Fordham University School of Law B.A., Fordham University Bar Admissions
More informationFortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY May 10, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company dedicated
More information9. IP and antitrust 52
9. IP and antitrust 52 Implications of recent cases and likely policy developments in 2017 Rewards for innovation through the existence and protection of intellectual property (IP) rights are crucial in
More informationCase 3:09-cv N-BQ Document 201 Filed 05/16/17 Page 1 of 13 PageID 3204
Case 3:09-cv-01736-N-BQ Document 201 Filed 05/16/17 Page 1 of 13 PageID 3204 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION CERTAIN UNDERWRITERS AT LLOYD S OF LONDON
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationFINANCIER DATA PROTECTION & PRIVACY LAWS ANNUAL REVIEW ONLINE CONTENT DECEMBER 2016 R E P R I N T F I N A N C I E R W O R L D W I D E.
R E P R I N T F I N A N C I E R W O R L D W I D E. C O M ANNUAL REVIEW DATA PROTECTION & PRIVACY LAWS REPRINTED FROM ONLINE CONTENT DECEMBER 2016 2016 Financier Worldwide Limited Permission to use this
More informationAREAS OF PRACTICE. Administrative Law. Alternative Dispute Resolution. Appellate Litigation. Asset Protection & Business Planning
AREAS OF PRACTICE Administrative Law Government authority and oversight extend to a wide range of individual, professional, business, and nonprofit activities. The attorneys of Hutchison & Steffen are
More informationFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationDEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT. Before the Full House Committee on Oversight and Government Reform.
Statement for the record: DEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT Before the Full House Committee on Oversight and Government Reform February 4, 2016 David A. Balto Law Offices of David
More informationThe Cost of Specialty Drugs: Payer Perspectives
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important
More informationJohn E. Heintz Partner Insurance Recovery Eye Street NW Washington, D.C
John E. Heintz Partner Insurance Recovery 1825 Eye Street NW Washington, D.C. 20006 +1.202.420.5373 jheintz@ John Heintz is a partner in Blank Rome s policyholder-only insurance recovery practice, formerly
More informationIpsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates
PRESS RELEASE Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates Paris (France), 26 April 2018 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical
More informationActavis, Valuation and Fairness Opinions
Actavis, Valuation and Fairness Opinions Adopting the Rule of Reason Approach to Evaluate Brand/Generic Agreements Through Valuation and Fairness Opinions February 2015 FTC Reverse Payment Settlement Statistics
More informationDrug Royalty II $701,420,000. Presentation to: San Diego County Employees Retirement Association
Drug Royalty II $701,420,000 Presentation to: San Diego County Employees Retirement Association November 2010 Profile Business Model Team Investment Criteria To acquire Royalty Streams on established commercialized
More information2017 YEAR END REVIEW
2017 YEAR END REVIEW 2017 was another year of significant growth and successes for EG&S We added 6 new attorneys, bringing our total number of attorneys to nearly 80. In our Securities Practice, we act
More informationCase 1:13-cv NLH-KMW Document 1 Filed 08/30/13 Page 1 of 19 PageID: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 1:13-cv-05238-NLH-KMW Document 1 Filed 08/30/13 Page 1 of 19 PageID: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY MARY ANNE CAPRIO, on behalf of herself and all others similarly situated,
More informationIntellipharmaceutics Announces Second Quarter 2018 Results
July 16, 2018 Intellipharmaceutics Announces Second Quarter 2018 Results TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationEric B. Bruce Lawyer WASHINGTON DC NEW YORK. Admissions
Eric B. Bruce Lawyer WASHINGTON DC 1919 M Street, NW Washington, DC 20036 +1 202 664 1903 NEW YORK 800 Third Avenue New York, New York 10022 +1 212 488 1203 eric.bruce@kobrekim.com A former high-ranking
More informationPinsent Masons in the UAE
Pinsent Masons in the UAE Pinsent Masons In the UAE Introduction Our UAE office, based in the heart of Dubai s financial district, combines local knowledge with an international experience to advise clients
More informationLigand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009 Ligand to Acquire Metabasis for Cash and Contingent Value Rights Ligand to Gain Fully Funded Partnership with Roche for Hepatitis and Promising Development-Stage Programs SAN DIEGO-- Ligand
More informationT M E. EDUCATION University of Pennsylvania (B.A., 1993)
JOHN P. BANG Senior Foreign Attorney (Member of New York & New Jersey Bars) Head of the International Arbitration and Litigation Practice Bae, Kim & Lee LLC T. 82-2-3404-0270 M. 82-10-2004-0270 E. john.bang@bkl.co.kr
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 02/20/14 for the Period Ending 02/20/14 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationAffimed Reports Financial Results for Second Quarter 2018 and Operational Progress
FOR IMMEDIATE RELEASE Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress Heidelberg, Germany, August 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 10-Q. PFIZER INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:11-cv-00569-LPS Document 6 Filed 08/15/11 Page 1 of 8 PageID #: 87 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PFIZER IRELAND PHARMACEUTICALS, WARNER-LAMBERT COMPANY,
More informationThe FCPA and Insurance Coverage: Five Strategies for Protecting Against the Financial Costs of an FCPA Claim
The FCPA and Insurance Coverage: Five Strategies for Protecting Against the Financial Costs of an FCPA Claim Jonathan M. Cohen and Katrina F. Johnson i In an era of high profile Wall Street prosecutions
More informationBRISTOL-MYERS SQUIBB COMPANY
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD
More informationANNUAL RESULTS 2015: END-OF-YEAR CASH POSITION OF 60M AND MAJOR PROGRESS IN THE DIAGNOSIS AND THE TREATMENT OF NASH
ANNUAL RESULTS 2015: END-OF-YEAR CASH POSITION OF 60M AND MAJOR PROGRESS IN THE DIAGNOSIS AND THE TREATMENT OF NASH Cash horizon to early 2017 Phase IIb clinical results for Elafibranor in NASH led to
More informationAttorney Advertising
Attorney Advertising For half a century, Caplin & Drysdale has been a leading provider of tax and related legal services to businesses, nonprofits, and individuals throughout the United States and around
More informationAstraZeneca V. EC The Advocate General s Opinion
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com AstraZeneca V. EC The Advocate General s Opinion Law360,
More informationriskinsights First Half 2017 Securities Suit Filings Continue at Exceptional Levels
riskinsights 1 SUMMER 2017 riskinsights First Half 2017 Securities Suit Filings Continue at Exceptional Levels Largely as a result of the continuing upsurge in the number of federal court merger objection
More informationCombination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014
Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014 David Dvorak President and Chief Executive Officer Jim Crines EVP, Finance, and Chief Financial Officer Cautionary Statement
More informationHalf-year financial report June 30, 2016
French société anonyme governed by an executive board and a supervisory board with a share capital of 2,694,782.70 euros composed of 53,895,654 shares with a nominal value of 0.05 euros each. Registered
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationFor more than 175 years, Baker Botts has been among the leading law firms in the world. Today, with 725 lawyers based in 14 offices around the world,
Tax Practice For more than 175 years, Baker Botts has been among the leading law firms in the world. Today, with 725 lawyers based in 14 offices around the world, the firm ranks among the largest global
More informationOncodesign: 2017 annual results
Oncodesign: 2017 annual results Operating revenue up 77% to 25.91 million R&D spending doubled to 13.9 million Solid operational execution and rigorous management of acquisitions despite various accounting
More informationLigand Provides Highlights from Today s Analyst Day Event
November 14, 2017 Ligand Provides Highlights from Today s Analyst Day Event Webcast available at www.ligand.com SAN DIEGO--(BUSINESS WIRE)-- At an Analyst Day event held today in New York City, Ligand
More informationMergers & Acquisitions
Mergers & Acquisitions A number of our corporate lawyers are well known as leaders in middle-market merger and acquisition work. Our M&A Group has cultivated a special legal and practical understanding
More informationServices and Capabilities. Health Care
Services and Capabilities Health Care Our team of experts offers an unmatched combination of economic credentials, industry expertise, and testifying experience. Health Care and Antitrust Introduction/Overview
More informationTrial Lawyers Committed to Excellence
Trial Lawyers Committed to Excellence our philosophy At Bancroft McGavin Horvath & Judkins, P.C., we are focused on and responsive to the needs of our clients and devoted to developing lasting attorney/client
More informationStephen E. Sellick MANAGING DIRECTOR
4350 N. Fairfax Dr. Suite 830 Arlington, VA 22203 1673 T 202.595.3566 F 866.485.9227 ssellick@gnarusllc.com www.gnarusllc.com OVERVIEW EXPERIENCE Mr. Sellick is the Managing Director and founder of Gnarus
More informationA Specialty Pharmaceutical Leader Focused in Pain and Neurology. Jefferies Global Healthcare Conference June 3, 2014
A Specialty Pharmaceutical Leader Focused in Pain and Neurology Jefferies Global Healthcare Conference June 3, 2014 Note on Forward-Looking Statements Statements made in this presentation that are not
More informationasialaw Dispute Resolution Review A special reprint for Dentons
asialaw www.asialaw.com Dispute Resolution Review 2017 A special reprint for Dentons Asialaw: Dispute Resolution ReVIEW 2017 China A Brief Introduction to Dispute Resolution in China Jiangtao Ma and John
More informationIN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA
IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA If you entered into a Loan Agreement with Western Sky that was subsequently purchased by WS Funding and serviced by CashCall, you
More informationE-Discovery and Data Management. Managing Litigation in the Digital Age
E-Discovery and Data Management Managing Litigation in the Digital Age Every day, 12 billion corporate e-mails are created. That number doubles annually. Litigation success starts with a sound ediscovery
More informationE-Discovery and Data Management. Managing Litigation in the Digital Age
E-Discovery and Data Management Managing Litigation in the Digital Age Every day, 12 billion corporate e-mails are created. That number doubles annually. Litigation success starts with a sound ediscovery
More information